Detecting Minimal Residual Disease in Neuroblastoma: The Superiority of a Panel of Real-Time Quantitative PCR Markers

Creative Commons License

Stutterheim J., Gerritsen A., Zappeij-Kannegieter L., YALÇIN B., Dee R., van Noesel M. M., ...More

CLINICAL CHEMISTRY, vol.55, no.7, pp.1316-1326, 2009 (SCI-Expanded) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 55 Issue: 7
  • Publication Date: 2009
  • Doi Number: 10.1373/clinchem.2008.117945
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Page Numbers: pp.1316-1326
  • Hacettepe University Affiliated: Yes


BACKGROUND: PCR-based detection of minimal residual disease (MRD) in neuroblastoma (NB) patients can be used for initial staging and monitoring therapy response in bone marrow (BM) and peripheral blood (PB). PHOX2B has been identified as a sensitive and specific MRD marker; however, its expression varies between tumors. Therefore, a panel of markers could increase sensitivity.